Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rare Disease OPEN-ing In PDUFA Possible For Drug Repurposing Advocates

Executive Summary

OPEN ACT would provide additional six months of exclusivity when existing drugs are approved for rare diseases; congressional debate over the measure could get bogged down in drug pricing issues.


Related Content

Pediatric Cancer Study Requirements Added To FDA User Fee Bill
User Fee Bill Could Become Ensnared In US Abortion Politics
Orphan Drug Act: Congressional, FDA, NORD Reviews Come Amid Pricing Debate
Shaping A Shkreli Bill: Voucher Abuse Solution May Stumble On FDA Effects
Will US FDA User Fee Reauthorization Bring More RATS?
Senate's Medical Innovation Bill Takes Cures' Shape
Genentech’s Actemra Receives Breakthrough For Systemic Sclerosis; Potential Future Beneficiary of OPEN ACT?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts